A New SV2A Ligand for Epilepsy

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.

Original languageEnglish (US)
Pages (from-to)587
Number of pages1
Issue number3
StatePublished - Oct 20 2016

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'A New SV2A Ligand for Epilepsy'. Together they form a unique fingerprint.

Cite this